Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A (original) (raw)
Figure 3
Mean percent growth inhibition activity of 3D7 parasites by GIA.
(A) WRAIR 20% serum pLDH GIA (B) NIH pLDH GIA at 4 mg/mL purified immunoglobulin. Results expressed as mean percent inhibition with serum from Day 70 using GIA methods described in Outcomes section. Low dose AMA-1/AS01B (n = 5), full dose AMA-1 in AS01B or AS02A (n = 14 in each).